Francesco M Marincola

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178
    Maria P Bettinotti
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 105:210-6. 2003
  2. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  3. pmc A decade plus of translation: what do we understand?
    Xiangdong Wang
    Department of Pulmonary Medicine, Fudan University Zhongshan Hospital, Shanghai 200032, China
    Clin Transl Med 1:3. 2012
  4. pmc A road map to Translational Medicine in Qatar and a model for the world
    Francesco M Marincola
    Office of the Dean, Weill Cornell Medical College in Qatar, Qatar Foundation, Education City, PO Box 24144, Doha, Qatar
    J Transl Med 10:177. 2012
  5. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  6. pmc Toward integrative cancer immunotherapy: targeting the tumor microenvironment
    Leisha A Emens
    Tumor Immunology and Breast Cancer Research Programs, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Transl Med 10:70. 2012
  7. pmc Expanding the perspective of translational medicine: the value of observational data
    Michael N Liebman
    Strategic Medicine, Inc, 231 Deepdale Drive, Kennett Square, PA 19348, USA
    J Transl Med 10:61. 2012
  8. pmc The immune score as a new possible approach for the classification of cancer
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, 15 Rue de l Ecole de Medecine F 75006 Paris, France
    J Transl Med 10:1. 2012
  9. pmc Supporting the advancement of science: Open access publishing and the role of mandates
    Lisa Phelps
    BioMed Central, 236 Gray s Inn Road, Floor 6, London, WC1X 8HB, UK
    J Transl Med 10:13. 2012
  10. pmc Reflections upon human cancer immune responsiveness to T cell-based therapy
    Ena Wang
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 61:761-70. 2012

Collaborators

Detail Information

Publications141 found, 100 shown here

  1. ncbi request reprint Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178
    Maria P Bettinotti
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 105:210-6. 2003
    ..Because of the modest immunological and clinical results, the present protocol has been discontinued as new routes of administration are being considered...
  2. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  3. pmc A decade plus of translation: what do we understand?
    Xiangdong Wang
    Department of Pulmonary Medicine, Fudan University Zhongshan Hospital, Shanghai 200032, China
    Clin Transl Med 1:3. 2012
    ..In this editorial, we will discuss the meaning of translational medicine, its goals and needs; we will summarize the remaining challenges and will provide a personal overview of the strategies that remain to be implemented...
  4. pmc A road map to Translational Medicine in Qatar and a model for the world
    Francesco M Marincola
    Office of the Dean, Weill Cornell Medical College in Qatar, Qatar Foundation, Education City, PO Box 24144, Doha, Qatar
    J Transl Med 10:177. 2012
    ....
  5. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  6. pmc Toward integrative cancer immunotherapy: targeting the tumor microenvironment
    Leisha A Emens
    Tumor Immunology and Breast Cancer Research Programs, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Transl Med 10:70. 2012
    ....
  7. pmc Expanding the perspective of translational medicine: the value of observational data
    Michael N Liebman
    Strategic Medicine, Inc, 231 Deepdale Drive, Kennett Square, PA 19348, USA
    J Transl Med 10:61. 2012
    ..We believe that this presents a significant opportunity that merits consideration in both the planning and analysis of large scale observational studies and can contribute greatly to expanding our approaches in translational medicine...
  8. pmc The immune score as a new possible approach for the classification of cancer
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, 15 Rue de l Ecole de Medecine F 75006 Paris, France
    J Transl Med 10:1. 2012
    ....
  9. pmc Supporting the advancement of science: Open access publishing and the role of mandates
    Lisa Phelps
    BioMed Central, 236 Gray s Inn Road, Floor 6, London, WC1X 8HB, UK
    J Transl Med 10:13. 2012
    ..Journal of Translational Medicine in affiliation with the Society for Immunotherapy of Cancer demonstrates how private and public organisations can work together for the advancement of science...
  10. pmc Reflections upon human cancer immune responsiveness to T cell-based therapy
    Ena Wang
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 61:761-70. 2012
    ....
  11. pmc How scientists use social media to communicate their research
    Laura Van Eperen
    J Transl Med 9:199. 2011
    ..The ability to communicate to the masses via social media is critical to the distribution of scientific information amongst professionals in the field and to the general population...
  12. pmc SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery
    Davide Bedognetti
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:155. 2011
    ..This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies...
  13. pmc An immunologic portrait of cancer
    Maria Libera Ascierto
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 9:146. 2011
    ..Here we reflect on commonalities and discrepancies among studies and on the genetic or somatic conditions that may cause this schism in cancer behavior...
  14. pmc Cancer vaccines at an inflexion point: what next?
    Adrian Bot
    Kite Pharma, Inc, Los Angeles CA 90024, USA
    J Transl Med 9:148. 2011
    ....
  15. pmc Combination therapy: the next opportunity and challenge of medicine
    Paolo A Ascierto
    Medical Oncology and Innovative Therapies Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G, Pascale, Napoli, Italy
    J Transl Med 9:115. 2011
    ..After recent successes in the immunotherapy field (Sepuleucel-T, ipilimumab) and the new promising small molecule therapies, cancer should be the next challenge for combination strategies...
  16. pmc Create a translational medicine knowledge repository - Research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how wi
    Bruce H Littman
    Translational Medicine Associates, L, L, C, Stonington, CT 06378, USA
    J Transl Med 9:56. 2011
    ..This searchable repository would become an invaluable resource for translational scientists and drug developers that could speed and reduce the cost of new drug development...
  17. pmc Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer
    James M Balwit
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:60. 2011
    ....
  18. pmc The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program
    James M Balwit
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:18. 2011
    ..Presentation slides, a Primer webinar and additional program information are available online on the society's website...
  19. pmc Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force
    Lisa H Butterfield
    Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA
    J Transl Med 8:130. 2010
    ..The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website...
  20. pmc Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy
    Vladia Monsurro
    Department of Pathology, University of Verona Medical School, Verona, Italy
    J Transl Med 8:10. 2010
    ..Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer mortality for which novel gene therapy approaches relying on tumor-tropic adenoviruses are being tested...
  21. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  22. pmc AAAS joins the Translational Medicine family
    Christian Brander
    Laboratori de Retrovirologia, , , Barcelona, Catalonia, Spain
    J Transl Med 7:32. 2009
    ....
  23. pmc Translational medicine--doing it backwards
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 8:12. 2010
    ..Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability 1...
  24. pmc Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma
    Valeria De Giorgi
    Molecular Biology and Viral Oncogenesis and AIDS Refer, Center, IST, Naz, Tumori Fond, G Pascale, Naples, Italy
    J Transl Med 7:85. 2009
    ..In the present study, a comparison of gene expression patterns has been performed by microarray analysis on liver biopsies from HCV-positive HCC patients and HCV-negative controls...
  25. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  26. pmc Translational Medicine is developing in China: a new venue for collaboration
    Xiangdong Wang
    Department of Respiratory Medicine, Biomedical Research Center, Fudan University Zhongshan Hospital, Shanghai, PR China
    J Transl Med 9:3. 2011
    ..Translational Medicine as an inter-disciplinary science is developing rapidly and widely and, in this article, we will place a special emphasis on China...
  27. pmc Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
    Andrea Worschech
    Genelux Corporation, San Diego Science Center, San Diego, California, USA
    BMC Genomics 10:301. 2009
    ..GLV-1h68 is an attenuated recombinant vaccinia virus (VACV) that selectively colonizes established human xenografts inducing their complete regression...
  28. pmc Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation
    Luigi Buonaguro
    Lab, Viral Oncogenesis and Immunotherapies and AIDS Reference Center, Department of Experimental Oncology, Istituto Nazionale Tumori Fond, G, Pascale, 80131 Napoli, Italy
    BMC Bioinformatics 9:S5. 2008
    ..Baculovirus-expressed HIV-1 Pr55gag Virus-Like Particles (HIV-VLPs) induce maturation and activation of monocyte-derived dendritic cells (MDDCs) with a production of Th1- and Th2-specific cytokines...
  29. pmc Bridging the divide between science and journalism
    Laura Van Eperen
    J Transl Med 8:25. 2010
    ..Reducing years of research into a headline can be extremely difficult and certainly doesn't come naturally to every scientist, so this article provides suggestions on how to work with the media to communicate your findings...
  30. ncbi request reprint The role of quantitative PCR for the immune monitoring of cancer patients
    Monica C Panelli
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 2:557-64. 2002
    ....
  31. doi request reprint The trouble with translational medicine
    Francesco M Marincola
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    J Intern Med 270:123-7. 2011
    ..This can only be achieved through the courageous effort of the research community to change the way biomedical research is funded, published and rewarded...
  32. ncbi request reprint Quiescent phenotype of tumor-specific CD8+ T cells following immunization
    Vladia Monsurro
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 104:1970-8. 2004
    ..In addition, the activation of TA-specific T cells by in vitro antigen recall and IL-2 suggests that a complete effector phenotype might be reinstated in vivo to fulfill the potential of anticancer vaccine protocols...
  33. pmc Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 8:4. 2010
    ....
  34. pmc Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy
    Marianna Sabatino
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Warren G Magnuson Clinical Center, NIH, Bethesda, MD, USA
    J Clin Oncol 27:2645-52. 2009
    ..High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified...
  35. ncbi request reprint Overview of melanoma vaccines and promising approaches
    Monica C Panelli
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bldg 10, R 1C711, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Curr Oncol Rep 6:414-20. 2004
    ....
  36. pmc GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells
    Silvia Selleri
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 6:17. 2008
    ..Whether this secretion affects in an autocrine loop the CTLs themselves is unknown...
  37. ncbi request reprint A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization
    Monica C Panelli
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bethesda, MD 20892 1502, USA
    Cells Tissues Organs 177:124-31. 2004
    ....
  38. pmc Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling
    Luciano Castiello
    Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 21:476-84. 2013
    ..In conclusion, using high-throughput technology we developed a method for the characterization of cellular therapies and the discovery of novel candidate quality assurance markers...
  39. pmc Antitumor vaccines, immunotherapy and the immunological constant of rejection
    Ena Wang
    National Institutes of Health, Department of Transfusion Medicine, Building 10, Room 1C711, Clinical Center, Bethesda, MD 20892, USA
    IDrugs 12:297-301. 2009
    ....
  40. pmc Polarized monocyte response to cytokine stimulation
    Dirk Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Genome Biol 6:R15. 2005
    ..Therefore, we tested whether polarized responses of MPs to pathogens are related to the influence of selected cytokines or represent a mandatory molecular switch through which most cytokines operate...
  41. ncbi request reprint Mechanism of immune response during immunotherapy
    Monica C Panelli
    Immunogenetics Section of the Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Yonsei Med J 45:15-7. 2004
    ....
  42. ncbi request reprint Common cancer biomarkers
    Christopher F Basil
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Cancer Institute, NIH, Bethesda, Maryland 20892 1184, USA
    Cancer Res 66:2953-61. 2006
    ....
  43. pmc Gene expression profiling of cutaneous wound healing
    Kavita Deonarine
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 5:11. 2007
    ..Genome wide transcriptional analysis tools promise to further define the global picture of this complex progression of events...
  44. pmc Genomic scale analysis of racial impact on response to IFN-alpha
    Zoltan Pos
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, and Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:803-8. 2010
    ....
  45. ncbi request reprint Active-specific immunization against melanoma: is the problem at the receiving end?
    Vladia Monsurro
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R 1C711 National Institutes of Health, Bethesda, MD, USA
    Semin Cancer Biol 13:473-80. 2003
    ....
  46. pmc Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis
    Valeria De Giorgi
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e56153. 2013
    ..Also characteristic gene signatures were identified of HCV-HCC progression for early HCC diagnosis. Conclusions: A diagnostic molecular signature complementing conventional pathologic assessment was identified...
  47. pmc IRF5 gene polymorphisms in melanoma
    Lorenzo Uccellini
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 10:170. 2012
    ....
  48. pmc The stable traits of melanoma genetics: an alternate approach to target discovery
    Tara L Spivey
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 13:156. 2012
    ..We hypothesized that genes steadily expressed by 15 melanoma cell lines (CMs) and their parental tissues (TMs) should be critical for oncogenesis and their expression most frequently influenced by their respective copy number...
  49. pmc IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 121:4746-57. 2011
    ....
  50. ncbi request reprint The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele
    Maurizio Provenzano
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 43:1567-74. 2003
    ..It was previously demonstrated that the CMV decamer (10-mer) peptide pp65(341-350), QYDPVAALFF, was able to induce CMV-specific CTLs in HLA-A*2402 CMV-seropositive individuals...
  51. pmc 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level
    Luciano Castiello
    Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 9:41. 2011
    ..Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is a growth factor widely used in immunotherapy both for in vivo and ex vivo applications, especially for its proliferative effects...
  52. ncbi request reprint Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Crit Rev Immunol 27:437-48. 2007
    ..This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs...
  53. pmc Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma
    Tae Hee Han
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunother 32:399-407. 2009
    ..There was no benefit of adding IL-1beta and TNF-alpha to LPS and IFN-gamma to produce mDCs...
  54. pmc Evaluation of normalization methods for two-channel microRNA microarrays
    Yingdong Zhao
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 8:69. 2010
    ..Findings from previous studies have sometimes been inconclusive or contradictory. Further studies to determine optimal normalization methods for miR microarrays are needed...
  55. ncbi request reprint A global approach to tumor immunology
    Ena Wang
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, 20892, USA
    Cell Mol Immunol 1:256-65. 2004
    ..In this review we will explore this hypothesis by reporting and summarizing most of our recent work in the frame of available literature on the subject...
  56. pmc Selection and validation of endogenous reference genes using a high throughput approach
    Ping Jin
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH Bethesda, MD 20892, USA
    BMC Genomics 5:55. 2004
    ..Whether this assumption is correct it is, however, still matter of debate. In this study, we searched for stably expressed genes in 384 cDNA array hybridization experiments encompassing different tissues and cell lines...
  57. ncbi request reprint Gene profiling for the prediction of tumor response to treatment: the case of immunotherapy
    Vladia Monsurro
    Department of Tranfusion Medicine, Immunogenetics Section, National Institutes of Health, Bethesda, Maryland 20892, USA
    Adv Exp Med Biol 593:86-94. 2007
  58. pmc MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells
    Jiaqiang Ren
    Department of Transfusion Medicine, Clinical Center, National Institute of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
    J Transl Med 7:20. 2009
    ..Non-coding microRNAs (miRNA) which regulate mRNA cleavage and inhibit encoded protein translation exhibit temporal or tissue-specific expression patterns and they play an important role in development timing...
  59. doi request reprint Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis
    Marianna Sabatino
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Warren G Magnuson Clinical Center, Biometrics Research Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1184, USA
    Cancer Res 68:122-31. 2008
    ..Our study provides important insights about the dynamics of cancer progression and supports the development of targeted anticancer therapies aimed against stable genetic factors that are maintained throughout the end stage of disease...
  60. pmc CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects
    Stefanie L Slezak
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 5:17. 2007
    ..Adoptive immune and vaccine therapies have been used to prevent cytomegalovirus (CMV) disease in recipients of hematopoietic progenitor cell transplants, but the nature of T cell responses to CMV have not been completely characterized...
  61. pmc Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 6:39. 2008
    ..The HSCs were compared to peripheral blood leukocytes (PBLs) from 7 subjects...
  62. pmc A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon
    Ena Wang
    Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 7:e40805. 2012
    ..The current study attempts to identify genetic markers likely to be associated with benefit from IFN-a2b treatment and predictive for survival...
  63. pmc Gene-expression profiling in vaccine therapy and immunotherapy for cancer
    Davide Bedognetti
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, and Trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    Expert Rev Vaccines 9:555-65. 2010
    ..We believe that the description of how the mechanism of immune-mediated tissue destruction occurs would contribute to our understanding of why it happens, thereby allowing us to develop more effective immune therapeutic strategies...
  64. pmc HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations
    Lorenzo Uccellini
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 56:86-94. 2012
    ..In an adjusted analysis, age, gender, racial ancestry, HIV-1 infection, HCV genotype, and IL28B rs12979860 genotype were all independently associated with HCV RNA...
  65. pmc Monocyte-derived DC maturation strategies and related pathways: a transcriptional view
    Luciano Castiello
    Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 60:457-66. 2011
    ....
  66. ncbi request reprint Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions
    Sara Deola
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunol 180:1362-72. 2008
    ..This observation provides a mechanistic explanation to previously reported experimental observations suggesting that B cells are required for T cell priming in vivo...
  67. ncbi request reprint Analysis of vaccine-induced T cells in humans with cancer
    Stefanie L Slezak
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Adv Exp Med Biol 684:178-88. 2010
    ..Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means ofeliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion...
  68. pmc Increased effector-target cell conjugate formation due to HLA restricted specific antigen recognition
    Ching Y Voss
    Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Immunol Res 45:13-24. 2009
    ..Since conjugate formation analysis does not require knowledge of the target antigen, this assay could potentially be used for enrichment of CTL directed against novel antigens...
  69. pmc Functional heterogeneity of vaccine-induced CD8(+) T cells
    Vladia Monsurro
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, and Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:5933-42. 2002
    ..In addition, CD45RA/CD27 expression may be more informative about the status of activation of circulating T cells than their status of differentiation...
  70. pmc Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes
    Simone Seiter
    Department of Transfusion Medicine, Center for Cancer Research, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:252-63. 2002
    ..These data provide direct enumeration of MART-1/MelanA and gp100/pMel17 reactivity ex vivo and in vitro in the context of HLA-A*0201...
  71. pmc Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
    Maria Libera Ascierto
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA
    BMC Cancer 11:451. 2011
    ....
  72. pmc Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
    Monica C Panelli
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center National Institutes of Health, Bethesda, MD 20892, USA
    Genome Biol 8:R8. 2007
    ..We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection...
  73. pmc Molecular immune signatures of HIV-1 vaccines in human PBMCs
    Alessandro Monaco
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health Bethesda, MD, USA
    FEBS Lett 583:3004-8. 2009
    ..This ex vivo screening strategy represents an efficient tool for guiding modifications/optimizations of vaccination strategies and understanding failures in individuals enrolled in clinical trials...
  74. ncbi request reprint Vaccination with T cell-defined antigens
    Monica C Panelli
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 4:697-707. 2004
    ....
  75. ncbi request reprint Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M
    Dirk Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, NIH Clinical Center, 10 Center Drive, Bethesda, MD 20892 1502, USA
    Cancer Immunol Immunother 53:817-24. 2004
    ..Since the final antigenic nonamer is not directly produced by the proteasome, additional further factors may influence the antigenic peptide availability, such as post-proteasomal processing and intracellular peptide transport...
  76. ncbi request reprint Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer
    Ena Wang
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 64:7279-87. 2004
    ..Finally, a small subset of genes is associated with lineage-specific oncogenesis, and these may provide information regarding the biological behavior of RCCs and facilitate diagnostic classification of RCCs...
  77. pmc Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians
    Xin Li
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 5:22. 2007
    ..In addition, we identified a putative haplotype rare in Tunisian patients with NPC that may serve as a genetic marker for further susceptibility studies...
  78. ncbi request reprint The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma
    Ena Wang
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD 20892 1502, USA
    Clin Cancer Res 13:7228-31. 2007
  79. ncbi request reprint Tumors as elusive targets of T-cell-based active immunotherapy
    Francesco M Marincola
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Trends Immunol 24:335-42. 2003
    ..Furthermore, we will discuss the information still required in order to understand the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization...
  80. doi request reprint The immunologic constant of rejection
    Ena Wang
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Trends Immunol 29:256-62. 2008
    ..Understanding this final effector pathway may suggest novel strategies for the induction or inhibition of tissue-specific destruction with therapeutic intent in cancer and other immune pathologies...
  81. pmc Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells
    Jeong Won Shin
    Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 48:647-57. 2008
    ....
  82. ncbi request reprint Spontaneous and treatment-induced cancer rejection in humans
    Ena Wang
    National Institutes of Health, Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bethesda, Maryland, 20892, USA
    Expert Opin Biol Ther 8:337-49. 2008
    ..On the other hand, it is also well documented that on rare occasions tumors can be dramatically destroyed by the host's immune response...
  83. doi request reprint Common pathways to tumor rejection
    Ena Wang
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, MD, USA
    Ann N Y Acad Sci 1284:75-9. 2013
    ..Here, we summarize progress in the understanding of its genesis, outline the difficulties, and propose a strategy for understanding the causes of tumor rejection...
  84. ncbi request reprint How to analyze ex vivo T-cell responses in cancer patients
    Dirk Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 1502, USA
    In Vivo 16:519-25. 2002
    ..We emphasize single cell methods and underline the importance of ex vivo methods without prior culturing...
  85. pmc Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration
    Monica C Panelli
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Genome Biol 3:RESEARCH0035. 2002
    ..In this study, we compared early changes in transcriptional profiles of circulating mononuclear cells with those occurring within the microenvironment of melanoma metastases following systemic IL-2 administration...
  86. ncbi request reprint Understanding the response to immunotherapy in humans
    Ena Wang
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1184, USA
    Springer Semin Immunopathol 27:105-17. 2005
    ....
  87. pmc Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis
    Tara L Spivey
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 9:174. 2011
    ..The role of NK cell, B cell and T-regulatory cell signatures are also addressed...
  88. pmc Stem cells in melanoma development
    Marianna Sabatino
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10 Room 1C711, Bethesda, MD 20892, United States
    Cancer Lett 279:119-25. 2009
    ..In this review, we provide an overview of findings and advances in CSCs research that are relevant to the initiation, natural history, and the response to treatment of malignant melanoma...
  89. pmc "Sequencing-grade" screening for BRCA1 variants by oligo-arrays
    Alessandro Monaco
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 6:64. 2008
    ..This system is particularly useful for the screening of long genomic regions with relatively infrequent but clinically relevant variants, while drastically cutting time and costs in comparison to high-throughput sequencing...
  90. ncbi request reprint The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness
    Monica C Panelli
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 11:3601-3. 2005
  91. ncbi request reprint Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells
    Maurizio Provenzano
    Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 25:342-51. 2002
    ..As a result, this method measures naturally induced immune reactions...
  92. pmc Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
    Ena Wang
    Infectious Disease and Immunogenetics Section IDIS, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology CHI, National Institutes of Health, Bethesda, Maryland 20892, USA
    BMC Med Genomics 4:38. 2011
    ..Animal studies documented a decrease in global toxicity and an increase in therapeutic effectiveness of chemotherapy when combined with PHY906...
  93. pmc MicroRNA expression differentiates histology and predicts survival of lung cancer
    Maria Teresa Landi
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland 20892 7236, USA
    Clin Cancer Res 16:430-41. 2010
    ..The molecular drivers that determine histology in lung cancer are largely unknown. We investigated whether microRNA (miR) expression profiles can differentiate histologic subtypes and predict survival for non-small cell lung cancer...
  94. pmc A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Building 10, Room 2B08, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:243-51. 2002
    ..This study established a nonmyeloablative-conditioning regimen that could be safely administered in conjunction with adoptive T-cell transfer and IL-2 in patients with metastatic melanoma...
  95. ncbi request reprint Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield?
    Simone Mocellin
    Immunnogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Tumori 88:437-44. 2002
    ..As a model, we will discuss the observed immune response to tumor antigen -specific immunization and its relationship with the systemic administration of IL-2...
  96. ncbi request reprint Gene expression profiling of anticancer immune responses
    Ena Wang
    National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Curr Opin Mol Ther 6:288-95. 2004
    ..As reviews on technological aspects of the genomic analysis of cancer are already available, this review will provide a speculative discussion about their potential usefulness...
  97. pmc Global transcriptional analysis for biomarker discovery and validation in cellular therapies
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Diagn Ther 13:181-93. 2009
    ..Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and miRNA expression microarrays in potency testing of cellular therapies are discussed...
  98. ncbi request reprint Tumor microenvironment and the immune response
    Silvia Selleri
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Surg Oncol Clin N Am 16:737-53, vii-viii. 2007
    ..We emphasize the critical role that future clinical investigations, led by surgical oncologists, may have for the assessment of the validity of the disparate hypotheses so far formulated at the bench side...
  99. ncbi request reprint Effects of storage time and exogenous protease inhibitors on plasma protein levels
    Saleh Ayache
    Immunogenetics Laboratory, Department of Transfusion Medicine, Warren G Magnuson Clinical Center National Institutes of Health, Bethesda, MD 20892 1184, USA
    Am J Clin Pathol 126:174-84. 2006
    ..The dramatic changes in protein levels during storage were independent of protease inhibitors and are likely due to cytokine production and/or release by leukocytes and platelets...
  100. ncbi request reprint Gene profiling of immune responses against tumors
    Ena Wang
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Immunol 17:423-7. 2005
    ..Future investigations should reframe scientific thinking when applied to humans, utilizing descriptive tools to generate novel hypotheses relevant to human disease...
  101. ncbi request reprint Transcriptional analysis of tumor-specific T-cell responses in cancer patients
    Dirk Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Crit Rev Immunol 22:449-62. 2002
    ..Recent work discussed in this review summarizes the complementarity of transcriptional analysis as an essential tool that, in addition to conventional methods, may deepen and broaden the characterization of tumor-specific T cells...